Medincell: The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults

The olanzapine long-acting injectable (TEV-’749 / mdc-TJK) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.

If approved, TEV-‘749 could help fill a significant unmet need in available schizophrenia treatment options by addressing the lack of a viable long-acting olanzapine formulation.

Teva is committed to advancing this innovative treatment option, strengthening its scientific leadership in complex neurological conditions as part of its Pivot to Growth strategy.

Regulatory News:

Medincell: The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults

Other newsrooms on this story

Related reading

Zypadhera : remise à disposition « indéterminée » du médicament antipsychotique

First drug to slow down progress of type 1 diabetes gets approval

Breakthrough drug that slows onset of type 1 diabetes set for UK release

Nuovi farmaci per l'Alzheimer in arrivo: chi potrà beneficiarne?

BioMarin to seek further approval of Voxzogo in form of short stature

IL-6 Drug Promising in Depression; U.S. More Anxious; AI Risks in Addiction…